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Abstract
Cyclin-dependent kinase (CDK)4 is a master integrator that couples mitogenic and antimitogenic
extracellular signals with the cell cycle. It is also crucial for many oncogenic transformation
processes. In this overview, we address various molecular features of CDK4 activation that are
critical but remain poorly known or debated, including the regulation of its association with D-type
cyclins, its subcellular location, its activating Thr172-phosphorylation and the roles of Cip/Kip CDK
"inhibitors" in these processes. We have recently identified the T-loop phosphorylation of CDK4,
but not of CDK6, as a determining target for cell cycle control by extracellular factors, indicating
that CDK4-activating kinase(s) might have to be reconsidered.
Background
At least during embryonic development in mice, CDK4
and its cousin CDK6, as well as their common regulatory
partners the three D-type cyclins, are not absolutely
required for cell cycle progression [1,2]. E-type cyclins and
CDK2 are similarly dispensable for embryo cell prolifera-
tion [3-6]. However, loss of CDK4 and CDK2 together
(but not combined loss of CDK6 and CDK2 [1]) results in
suppressed pRb phosphorylation at midgestation, more
severe size reduction in the different organs, embryonic
lethality due to heart failure and severe impairment of
embryo cell proliferation in culture [7]. Previously, silenc-
ing of CDK2 was found to block proliferation in triple cyc-
lin D knockout embryo fibroblasts but not in their wild-
type counterparts [2]. This demonstrates the limits of the
once unexpected plasticity of cell cycle regulation in mam-
malian embryo development and of the possible compen-
sation of functions operated by both kinds of G1 phase
cyclin-CDK complexes.
That does not mean that cell cycle progression in adult dif-
ferentiated tissues could normally occur without CDK4
and/or CDK6. For instance CDK4 is dispensable for pre-
natal development of the pituitary but indispensable for
postnatal proliferation of somato/lactotrophs [8]. Simi-
larly, cyclins D2 and D1 are essential for postnatal but not
prenatal pancreatic beta-cell growth [9]. Another good
illustration is the appearance of the cell cycle requirement
for cyclin D3 associated with the maturation of T lym-
phocyte [10] or late stages of neutrophil development
[11]. Indeed, first cell divisions in the mammalian
embryo depend on maternal transcripts and proteins, and
then in most differentiating lineages cell cycle might pro-
ceed without most of the restrictions that control adult
cell proliferation [12]. Many embryo cell cycles have a
short G1 phase and do not pause in a G0 stage, and thus
all the cell circuitry involved in the signalling of cell cycle
re-entry from G0 might be partly dispensable until rela-
tively late developmental stages. CDK1 can be activated
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development [13], leading to the perhaps oversimplified
vision of the embryonic cell cycle as a basic module
resembling the yeast cell cycle that depends on only one
CDK. During differentiation, different combinations of
the six possible cyclin D1/2/3-CDK4/6 complexes may
become adjunct to (plugged in) this core cell cycle mod-
ule to couple its execution to the various intracellular cas-
cades that transduce signals needed in the whole
organism homeostasis.
During later stages of development and in adults, D-type
cyclins CDK4/6 complexes thus appear to play essential,
yet facilitative, roles as master integrators of the various
mitogenic and antimitogenic signals conveyed by the
extracellular environment. They are also regulated in
response to intracellular mechanisms that sense the meta-
bolic state of the cell, including its energetic and biosyn-
thetic status, and respond to various stresses. According to
their tissue-specific, but greatly overlapping, expression
patterns, individual D-type cyclins have been shown to be
required for proliferation and development of specific tis-
sues (as reviewed in [14]), such as mammary gland and
retina for cyclin D1, gonads, B-lymphocyte and pancreatic
β-cells for cyclin D2, and maturation of T-lymphocytes for
cyclin D3. Like cyclin D1-null mice, CDK4-null mice are
smaller, but additionally display abnormalities seen in
cyclin D2-deficient mice, including impaired develop-
ment of pancreatic β-cells [15], whereas CDK6-null mice
suffer from haematopoietic defects (reviewed in [14]). It
remains somewhat unclear if these specific phenotypes
depend only on the particular tissue-specific expression
profiles of the various D-type cyclins and their association
with CDK4 or CDK6, or might also be related to some
non-overlapping functions of their different complexes.
At least partial compensation between different D-type
cyclins has been well demonstrated [16-18], but it has not
been systematically explored in adult tissues. It has
recently appeared that CDK6 cannot compensate CDK4
loss in a CDK2-null background [19], but CDK6 might
have specific functions in blocking some differentiation
processes [20]. Differentiation is often associated with
dramatic D-type cyclins' expression switches. In several
adult mammalian tissues, cyclin D1 localizes to prolifera-
tive layers, whereas cyclin D3 is often highly expressed in
the adjacent compartment where differentiation takes
place [21-24]. Cyclin D3 replaces cyclin D1 during myo-
genesis [25,26], adipogenesis [27], or at the pre-TCR
developmental stage during T lymphocyte maturation
[10].
The six D-type cyclin-CDK4/6 complexes phosphorylate
and inactivate the cell cycle/tumor suppressor proteins of
the pRb family (p105Rb, p107, p130Rb2) [28-33]. This
function is indeed essential since the CDK4/6 inhibitor
p16 or neutralization of cyclin D1 do not prevent cell
cycle progression in pRb-defective cells [34-36]. However,
there are also some indications that CDK4/6 can phos-
phorylate other substrates. Recently, CDK4 (and CDK2)
was demonstrated to phosphorylate and inactivate Smad3
[37]. Direct phosphorylations by CDK4 of the nucleolar
transcription factor upstream binding factor (UBF) [38],
the replication licensing factor Cdt1 [39], the bone-spe-
cific transcription factor Runx2 [40], and possibly TSC2
[41] have been reported. Differential phosphorylation of
unidentified substrates by cyclin D1-CDK4 or cyclin D3-
CDK4/6 was observed [42]. Moreover, cyclin D3 com-
plexes more efficiently phosphorylate p130 than do cyclin
D1 complexes [43]. Finally, CDK4 and CDK6 may have
different preferences for phosphorylation of specific sites
in pRb protein [44], and we have recently found distinct
specificities of pRb phosphorylation by CDK4 activated
by cyclin D1 or cyclin D3 [45].
CDK4 activity is deregulated in many human tumors
[46,47]. It has been recently confirmed to be crucial for
various oncogenic transformation processes [2,48-53].
Deregulation does not only result from oncogenic hyper-
activation of mitogenic signalling cascades ending at D-
type cyclin gene transactivation. Every particular compo-
nent of "the Rb pathway" act as tumor suppressors or pro-
tooncogenes (reviewed in [14,46,47]). Amplification or
rearrangement of the genes encoding cyclins D1, D2 and
D3 have been found in many human cancers and leukae-
mias. Oncogenic mutations of cyclin D1 enforcing its
nuclear accumulation have been recently described [54].
Loss of p16 by mutation, deletion or gene silencing is
extremely frequent. CDK4 itself is overexpressed as a
result of gene amplification, or subject to a mutation that
renders it insensitive to p16. Interesting models of CDK4/
6 deregulation are also provided by some oncogenic
viruses. Cyclin K encoded by Kaposi's sarcoma-associated
herpesvirus strongly activates CDK6 and CDK4 through
original mechanisms [55], and the Tax oncoprotein of
human T-cell leukaemia virus type 1 directly binds to and
activate CDK4, which involves enhanced cyclin D interac-
tion and suppression of inhibition by p16 [56,57].
CDK4 regulation
The so widespread deregulation of CDK4 in cancers
underscores the necessity to fully understand the various
mechanisms involved in its activation process. As initially
considered, mitogens activate CDK4/6 by inducing at
least one D-type cyclin (D1, D2 and D3) to concentra-
tions allowing to overcome an inhibitory threshold
imposed by INK4 CDK4/6 inhibitory proteins [58]. These
proteins (p15, p16, p18, p19) bind to the catalytic
domain of the isolated CDK4/6, thus preventing cyclin
association and activation [59-61]. In short, the synthesis
of cyclin D1 and cyclin D2 is stimulated by variousPage 2 of 16
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treatments (though cyclin D3 is often associated with qui-
escent cells [21]). On the opposite, the accumulation of
INK4 inhibitory proteins is increased in anti-proliferative
situations, such as senescence (p16), TGFβ treatment
(p15)[62] or specific differentiation processes (p18 and
p19)[63]. In some systems, CDK4 expression itself is
increased, which can potentially titrate INK4 proteins,
explaining for instance that overexpression of CDK4 can
relieve TGFβ inhibition of proliferation [64].
Increased expression of a D-type cyclin is clearly not suffi-
cient to activate CDK4. In this overview, we will address
various molecular features of CDK4 activation that are
critical but remain poorly known or debated, including
the regulation of its association with D-type cyclins, its
subcellular location, its activating Thr172-phosphoryla-
tion and the roles of Cip/Kip CDK "inhibitors" in these
processes. We will often evocate questions raised by the S-
phase entry in a specific model system that we have char-
acterized, the primary culture of canine thyroid epithelial
cells [65,66]. Indeed, this physiologically relevant model
displays several interesting features, including the coexist-
ence of two very distinct mitogenic pathways [67,68],
which both require CDK4 activity [69,70] : (i) a canonical
mitogenic stimulation by growth factors associated with
reversible dedifferentiation, and (ii) a mitogenic stimula-
tion associated with enhanced thyroid function and dif-
ferentiation expression by the physiological stimulus,
TSH, which signals only through elevation of cellular
cyclic AMP levels without activating most of the classical
intermediates of growth factor-dependent cascades
(including Ras, ERKs and PI3-kinase pathways)[65,71-
73]. Paradoxically, this cAMP-dependent triggering of cell
cycle progression involves an accumulation of the p27kip1
CDK inhibitor [74] but not of the D-type cyclins [70], as
observed in cell systems where cAMP blocks G1 phase
progression [75,76]. Cyclin D3 is nevertheless required in
this differentiation-compatible mitogenic stimulation,
but not for the proliferation stimulation by growth factors
that induce the other D-type cyclins [70]. This specific
requirement for cyclin D3 is consistent with the emerging
concept that cyclin D3 might be more specifically
involved in specialized cell cycles associated with mainte-
nance or induction of differentiation [10,21,45].
Regulated assembly of D-type cyclin-CDK4 complexes
Early studies by the group of Sherr have shown that D-
type cyclins and CDK4 do not assemble spontaneously in
vitro, but nevertheless can form active complexes when
marinated with an extract of proliferating NIH3T3 cells,
but not (as reported but not shown) with extracts of
growth-factor deprived cells [77]. Since the association of
CDK4 with the cyclin D was not shown in these experi-
ments, this assay could not discriminate between assem-
bly and activation activities. Nevertheless, using NIH 3T3
cells engineered to constitutively express both cyclin D3
or cyclin D1 and CDK4, the same authors showed that the
formation of cyclin D1/3-CDK4 complexes depends on
serum stimulation [78], which can be replaced by expres-
sion of an activated form of MEK1 [79]. However, in a
similar experimental setting, Ladha et al [80] found that
overexpressed cyclin D1 can efficiently assemble with
endogenous CDK4 to form inactive complexes in serum-
deprived NIH 3T3 cells. Cyclin D3-CDK4 complexes are
also constitutively assembled in G0 cells such as serum-
deprived Balb c 3T3 cells [81] and T98G cells [82].
The dog thyrocyte system has provided the first evidence
for a critical regulation of D-type cyclin-CDK4 assembly
by a physiological mitogenic stimulus [70]. In these cells,
cyclin D3 is abundantly expressed depending in part on
the presence of comitogenic factors (insulin and carba-
chol), whereas CDK4 is constitutively expressed. TSH and
cAMP trigger the entry into S-phase at least in part by pro-
moting the assembly of required cyclin D3-CDK4 com-
plexes [70,83-85]. Other examples of regulation of the
formation of D-type cyclin-CDK4/6 complexes unex-
plained by modulations of cyclin D or CDK4/6 presence
were found in B lymphocytes [86], or FSH-stimulated
granulosa cells of hamster preantral follicles [87].
Such findings led to the suggestion that an assembly factor
might be required for the assembly of cyclin D-CDK4
complexes [77,78]. In recent years, several interactors of
cyclins D or CDK4/6 have been proposed to play a role in
the formation of their complex. They are discussed below:
p21/p27
At variance with initial reports (reviewed in [59]), Cip/Kip
CDK inhibitors (p21cip1, p27kip1) have been paradoxically
found to be associated with a pRb-kinase activity ascribed
to CDK4 [82,88-91]. As they possess distinct binding
domains for cyclins and CDKs, they were proposed as the
elusive adaptors for the assembly of D-type cyclin-CDK
complexes. Indeed, LaBaer and colleagues found that p21
and p27 can promote the formation of these complexes in
vitro or in cotransfected cells (yet only p21 could support
the pRb-kinase activity) [90]. p21 and p27 were even con-
cluded to be essential for this function, on the basis of the
lack of detectable D-type cyclin-CDK complexes in p21/
p27-null mouse embryonic fibroblasts [92]. Nevertheless,
these authors noticed that phosphorylation of pRb on
Ser780 (a site specifically phosphorylated by CDK4/6)
was unaffected. Moreover, D-type cyclin levels were also
much reduced, which may in part explain the failure to
detect their complexes with CDK4/6 [92]. Indeed, in sim-
ilar experimental settings other authors more recently
reported that p21 and p27 do stabilize cyclin D3-CDK4
[93] and cyclin D1-CDK4 [94], but are not required forPage 3 of 16
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ited by p16. Moreover, Pledger's group claimed that only
the minor fraction of cyclin D3-CDK4 complexes devoid
of CIP/KIP proteins are active as pRb-kinases [95].
The case for p21 as a positive regulator of D-type cyclin-
CDK4 complexes is nevertheless well supported. In vari-
ous cell systems, p21 is transiently induced in G1 by
mitogenic factors through the Ras/Raf/ERKs cascade,
which is associated with increased CDK4 activity [82,96-
100]. Such p21 inductions indeed appear to play a posi-
tive role in cell proliferation, as shown by silencing of p21
expression by antisense oligonucleotides or RNA interfer-
ence [98,101-103]. However, whether the positive role of
p21 is mediated by enhanced assembly of D-type cyclin-
CDK4 remains to be ascertained. In MCF-7 cells, p21 anti-
sense markedly reduced cyclin D1 expression [102].
Moreover, inhibition by rapamycin of p21 expression,
p21 binding to cyclin D1-CDK4 and activation of this
complex were not associated with reduction of cyclin D1-
CDK4 assembly [104].
The TSH (cAMP)-dependent assembly of active cyclin D3-
CDK4 complexes in dog thyrocytes is clearly independent
of p21, which is weakly expressed and repressed by TSH
[100]. Instead, TSH stimulates the accumulation of p27
[74], which to our knowledge provides a unique such an
example in a mitogenic stimulation. Since p27 does asso-
ciate with cyclin D3-CDK4 without impairing its pRb-
kinase activity in TSH-stimulated cells [91], it would con-
stitute a likely candidate as the assembly factor. However,
the 2–3-fold increase of p27 levels could not plausibly
explain the 10–20-fold increase of cyclin D3-CDK4 com-
plexes induced by TSH. Moreover, inhibition by TGFβ of
TSH-stimulated cyclin D3-CDK4 activity is associated
with a reduction of the binding of cyclin D3 and CDK4 to
p27, but not of the assembly of the cyclin D3-CDK4 com-
plex [85,91]. At variance with Labaer et al [90], we were
unable to detect any in vitro assembly activity of p27 for
cyclin D3 and CDK4, even in conditions that allow the
binding of p27 to pre-assembled cyclin D3-CDK4 com-
plexes ([82], unpublished results). This is in agreement
with previous studies showing that abundant p27 in G0
cells is unable to assemble ectopically expressed cyclin D3
into CDK4 complexes in serum-starved fibroblasts [78].
Finally, whether the formation of D-type cyclin-CDK
complexes would indeed require an assembly factor
remains doubtful. The efficient assembly of strongly over-
expressed ectopic cyclin D3 and CDK4 in CHO cells can-
not be explained by low endogenous levels of p21 or p27
[82]. Similarly, the efficient assembly of D-type cyclins
and CDK4 co-produced in insect cell by baculoviral infec-
tion is known for a long time [77,82]. We have been una-
ble to detect insect cell proteins stoichiometrically
associated with these very abundant complexes (Bocks-
taele, unpublished results), in agreement with the appar-
ent size of 70 kDa reported for cyclin D2-CDK4
complexes produced in insect cells [89]. However, the
native active cyclin D1-CDK4 holoenzyme has been char-
acterized as a complex with a molecular mass ranging
from 150 to 200 kDa [105,106].
Other mechanisms should thus be envisaged to explain
the regulated formation of D-type cyclin-CDK complexes.
Phosphorylations of cyclin D3 do not appear to be
involved in TSH-dependent cyclin D3-CDK4 assembly in
thyrocytes, since all the main phosphorylated and
unphosphorylated forms of cyclin D3 separated by two-
dimensional (2D) gel electrophoresis were found in unal-
tered relative proportions in CDK4 complexes [91]. More-
over, combined mutations of a series of putative
phosphorylation sites of cyclin D3 (T283A, T117A,
S133A, S264A) did not affect its binding to CDK4 and
CDK4 activation in CHO cells (Bockstaele, unpublished
data).
INK4
Presence of INK4 proteins obviously affects D-type cyclin-
CDK association [105]. Parry and collaborators reported
that overexpression of p21 can promote the association of
D-type cyclins with CDKs by counteracting their binding
to INK4 proteins [106]. Conversely, increased expression
of p15 in response to TGFβ [107-109], ERK-dependent
p16 up-regulation [110], or p18 up-regulation by proges-
tin [111] destabilize D-type cyclin-CDK complexes and
mobilize p27. Defective p16 expression in tumor cells is
thus very likely to contribute to constitutive cyclin D3-
CDK4/6 assembly as we observe it in glioma T98G cells
[82]. However, INK4 proteins are not generally down-reg-
ulated by mitogenic stimulations, and thus are unlikely
involved in stimulated assembly of D-type cyclin-CDK
complexes. Interestingly, a phosphorylation (Ser152) of
p16 correlates with CDK4 association in human fibrob-
lasts [112]. Regulation of this phosphorylation and its
impact on p16-binding to CDK4 remain to be deter-
mined.
Chaperone proteins
Assembly of D-type cyclin and CDK4 likely depends on
proper folding of both subunits. Binding to the chaperone
HSP90 via p50cdc37 stabilizes CDK4 [113,114], competes
with p16 and thus would facilitate the assembly of a com-
plex between CDK4 and cyclin D1 [115]. Accordingly,
mutations of CDK4 within its ATP-binding domain
(G15A and G18A), which preclude Cdc37-CDK4 complex
formation, also greatly reduce binding of CDK4 to cyclin
D1 [116]. Upon release from Cdc37-HSP90 interaction,
properly folded newly synthesized CDK4 could thus
directly assemble with D-type cyclins, preferentially to thePage 4 of 16
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mitogenic regulation at this level has not been defined. In
another recent development, Diehl and collaborators
have identified Hsc70 as at least one of the probable miss-
ing component of the active cyclin D1-CDK4 holoenzyme
of NIH 3T3 cells [117]. Hsc70-cyclin D1 interaction is
stimulated by serum and would promote stabilization of
newly synthesized cyclin D1, thereby increasing its availa-
bility for assembly with CDK4. Nevertheless, Hsc70 does
not appear to assemble the cyclin D1-CDK4 complex. Fur-
thermore, interaction between Hsc70 and endogenously
expressed cyclin D1 was hardly detectable [117]. In dog
thyrocytes stimulated by TSH, we also easily identified
Hsc70 from two-dimensional gel separation of co-immu-
noprecipitations by cyclin D3 and CDK4 antibodies.
Unfortunately, unspecific association of Hsc70 to mock
immunoprecipitations (done with normal mouse serum)
that could not be displaced by high salt washings, as well
as our failure to detect endogenously expressed cyclin D3
and CDK4 in Hsc70 immunoprecipitations, have pre-
vented us from further investigating this interaction
(Paternot, unpublished results).
SEI-1
p34SEI-1, also known as TRIP-Br1, has been separately
identified as a p16 binding protein [118] and as a tran-
scriptional regulator that can functionally contact DP-1
and co-activate E2F-1/DP-1 transcriptional activity [119].
NIH 3T3 cells engineered to overexpress SEI-1 are anchor-
age-independent and tumorigenic, and amplification of
SEI-1 gene is commonly detected in ovarian cancers [120].
SEI-1 is induced by serum, and its ectopic expression
allows the formation of active CDK4 complexes that con-
tain both p16 and cyclin D1. SEI-1 might thus facilitate
the assembly of cyclin D1-CDK4 complexes by counter-
acting inhibitory effects of INK4 proteins [118]. Physio-
logical relevance of this interesting mechanism remained
doubtful, however, since complexes containing both p16
and cyclin D1 are not generally observed [60]. Indeed, the
same authors showed in a subsequent study that expres-
sion of p16 blocks the pRb-kinase activity associated with
ectopically expressed SEI-1 [94]. Ablation of SEI-1/TRIP-
BrI and TRIP-Br2 expression suppresses serum-induced
cyclin E expression and prevents S-phase entry [121].
Whether this results from an impairment of CDK4 com-
plex activation or of E2F-dependent transcription has yet
to be defined.
Gankyrin
The oncoprotein gankyrin [122] is a seven-ankyrin-repeat
protein that interacts with pRb, increases phosphorylation
of pRb by CDK4, and also increases the binding of p53 to
MDM2 [123]. In hepatocytes, gankyrin expression is
increased by mitogenic stimulation [124]. A search for
interaction partners of transfected gankyrin has identified
CDK4 [125], and gankyrin competes with p16 for binding
to CDK4 in reconstitution experiments [126]. It is not
known if gankyrin binds to monomeric CDK4 or CDK4
complexed with D-type cyclins.
Fbxo7
Recently, the F-box protein Fbxo7 was identified in a two-
hybrid yeast screen using the viral cyclin of Herpesvirus
saimiri as a bait [127]. Fbxo7 turned out to specifically
interact in vitro and in intact cells with CDK6 (but not
CDK4). Whereas knockdown of Fbxo7 reduces p27
expression and association of CDK6 with D-type cyclins,
Fbxo7 fails to assemble cyclin-CDK6 complexes in vitro,
and ectopic expression of Fbxo7 only moderately
enhances CDK6 association with D-type cyclins and pRb-
kinase activity. Despite this rather modest effect, overex-
pression of Fbxo7 transforms NIH 3T3 cells in a CDK6-
dependent manner [127], which does not rule out an
implication of other Fbxo7 interactors. Regulation of
Fbxo7 by mitogenic factors was not reported.
To conclude, the assembly of D-type cyclin-CDK4/6 com-
plexes is a highly regulated process. Only p21 or p27 have
been found to be stoichiometrically present in these com-
plexes. However, they are not required for the assembly of
D-type cyclin-CDK complexes, though they can obviously
stabilize them. INK4 proteins clearly restrict cyclin-CDK
assembly, but regulation at this level has not been deter-
mined. Mainly in overexpression systems, other interest-
ing interactors of CDK4/6 or D-type cyclins have been
demonstrated. They could influence the conformation of
the cyclin or CDK subunit, and facilitate either the release
of CDK4/6 from its complex with inhibitory INK4 pro-
teins or the association of the CDK with the cyclin. Never-
theless, much additional experimental evidence is needed
to demonstrate the physiological relevance and regulation
of these new interactions. Molecular masses of the D-type-
cyclin-CDK4/6 and their complex with p21/p27 are pre-
dicted to be about 70 and 100 kDa, respectively. Such
complexes do exist in intact cells. On the other hand, the
missing component(s) of the abundant 150–200 kDa
active CDK4/6 complexes that have been demonstrated in
various cell systems remain to be identified.
Regulated nuclear translocation of D-type cyclin-CDK4 
complexes
D-type cyclin-CDK4/6 complexes should accumulate in
the nucleus in order to phosphorylate their nuclear sub-
strates including pRb, p107 and p130. Moreover, the
activity of CDK4/6 requires their activating phosphoryla-
tion on Thr172/177 by the CDK-activating kinase (CAK),
which is a nuclear holoenzyme (but see discussion
below). Accordingly, a mutant of cyclin D1 that assembles
with CDK4 but prevents its nuclear localization (but also
its activation by CAK in vitro) dominantly inhibits thePage 5 of 16
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ectopic expression (together with CDK4) of a nucleus-tar-
geted variant of cyclin D1 but not of wild-type cyclin D1
promotes reentry of cardiomyocytes into cell cycle, sug-
gesting a critical role of cyclin D1 nuclear import [129].
Recently, the oncogenic potential of mutations that pre-
vent the nuclear export of cyclin D1 has been demon-
strated [54,130]. Nuclear translocation of cyclin D1 and
CDK4 during mitogenic processes has been observed in
vivo, including in rat liver regeneration [131] and in the
estrogen-induced proliferation of uterine epithelium
[132].
D-type cyclins and CDK4/6 do not possess obvious
nuclear localization sequences. Furthermore, depending
on its Thr286 phosphorylation by GSK3β which allows its
binding to the exportin CRM1, cyclin D1 is exported to
the cytoplasm during S-phase in fibroblasts [133]. Other
CDK4/6 binding proteins including INK4 proteins
[34,107] and Cdc37 [113] are mostly cytoplasmic pro-
teins. By contrasts, Cip/Kip proteins contain a well charac-
terized bipartite nuclear localization signal (NLS) in their
C-terminus. Enforced expressions of p21, p27 and p57
were thus demonstrated to localize D-type cyclin-CDK
complexes to the nucleus [82,90,107,134]. These proteins
really determine the location of CDK4, as the deletion of
the NLS of p21 and p27 relocalize CDK4 to the cytoplasm
[82,90,107]. In NIH 3T3 cells, p21 promotes the nuclear
accumulation of cyclin D1 by preventing its association
with CRM1 [135]. Like its assembly [79], the nuclear accu-
mulation of cyclin D1-CDK4 appears to depend on MEK
activity in NIH 3T3 cells [136].
To our knowledge, dog thyrocyte primary cultures have
provided the first example of a nuclear translocation of
endogenously expressed CDK4 in response to various
mitogenic stimulations, including TSH and cAMP, growth
factors and phorbol esters [70]. CDK4 nuclear transloca-
tion elicited by TSH (cAMP) correlates in individual cells
with G1 and S-phase progression [70] and depends on the
presence of comitogenic factors (insulin and carbachol)
[83,84]. In thyrocytes stimulated by growth factors, CDK4
nuclear import perfectly correlates in individual cells with
binding to cyclin D1 and up regulated nuclear p21 [45],
whereas it is associated with cyclin D3 and nuclear accu-
mulation of p27 in TSH-stimulated cells [85,91]. The
inhibition by TGFβ of TSH-elicited nuclear import of both
CDK4 and cyclin D3 is explained by their reduced associ-
ation with nuclear p27. Interestingly, the TSH-dependent
assembly of cyclin D3-CDK4 complexes is not affected by
TGFβ, which dissociates the nuclear import from the
assembly, and points out the critical role of p27 in the
subcellular location but not in the assembly of cyclin D3-
CDK4 [85,91]. Intriguingly, the nuclear translocation of
cyclin D3 in thyrocytes is associated with the unmasking
of its DCS-22 epitope (aa 241–260), which suggests a con-
formational change of cyclin D3 or a modification of its
interaction with other proteins [70,85]. At variance with
the situation described for the export of Thr286-phospho-
rylated cyclin D1 in fibroblasts [133], cyclin D3 steadily
accumulates in nuclei during S and G2-phases [70], and
the phosphorylation of cyclin D3 at Thr283 by GSK3β
does not signal its nuclear export [137].
In many cell systems, late G1 phase progression depends
on the activity of the calcium-binding protein calmodu-
lin. Pharmacological inhibition of calmodulin in NRK
fibroblasts inhibits the activity of cyclin D1-CDK4 com-
plexes by inducing their translocation to the cytoplasm,
providing another early example of regulation of D-type
cyclin-CDK4 complex localization dissociated from the
modulation of its assembly [138]. This calmodulin-
dependent nuclear accumulation of cyclin D1-CDK4-p21
complexes appears to depend on a direct calcium-depend-
ent binding of p21 to calmodulin [139].
As p21 and p27 clearly determine the subcellular location
of D-type-cyclin-CDK4 complexes, posttranslational
modifications that alter the nuclear location of p21 or p27
should also affect the localization of CDK4 and its activ-
ity. The impact on p21 subcellular location of its Thr145-
phosphorylation by overactivated Akt or Pim1 remains
controversial [140-143]. The major phosphorylation of
p27kip1 at Ser10 [144] has been reported to cause the
nuclear export of p27kip1 during G1 phase progression in
fibroblast cell lines [145-147]. The inactivation of p27kip1
by its cytoplasmic mislocalization in different breast can-
cer cell lines is caused by p27kip1 phosphorylation within
the NLS at Thr157 by overactivated Akt/PKB [148-150].
Thr157 phosphorylation of p27 by cytoplasmic Akt,
which prevents p27 binding to importin α and thus
nucleus re-entry, appears itself to depend on prior Ser10-
phosphorylation of p27 required for its nuclear export
[151]. This relocalization of p27 into the cytoplasm is
believed to critically contribute to the activation of cyclin
E-CDK2. Unfortunately, its impact on CDK4 complex
localization and activity was not investigated in the above
referenced studies. Ser10 phosphorylation of p27 is
unlikely to be sufficient for nucleus export. Nuclear p27 is
abundantly phosphorylated at Ser10 in dog thyrocytes
and p27-transfected CHO cells [82,91]. In dog thyrocytes,
the phosphorylation profile of p27 (as resolved by isoe-
lectric focusing separation) and its Ser10-phosphoryla-
tion are not consistently modulated by cAMP, TGFβ,
insulin, growth factors, or pharmacological inhibition of
MEK- or PI3-kinase-dependent signalling, and all the
(un)phosphorylated forms of p27 are found in unaltered
proportion in cyclin D3-CDK4 complexes [82,91].Page 6 of 16
(page number not for citation purposes)
Cell Division 2006, 1:25 http://www.celldiv.com/content/1/1/25To conclude, the instrumental role of the up-regulation by
mitogenic treatments of either p21 or p27 in the required
nuclear import of D-type cyclin-CDK4 complexes is well
demonstrated in a variety of cell systems. It appears to be
dominant over mechanisms that promote nucleus export
of CDK4 and D-type cyclins, including the GSK3β-
dependent phosphorylation of cyclin D1. A significant
role for posttranslational modifications of p21 and p27 in
the regulation of this process has yet to be firmly demon-
strated.
Regulated activity of D-type cyclin-CDK4 complexes
The assembly of D-type cyclin-CDK4/6 complexes and
even their nuclear location are not sufficient for their cat-
alytic activity. Upon mitogenic stimulation of quiescent
cells, appearance of the pRb-kinase activity of CDK4 is
often delayed compared to the formation of D-type cyc-
lin-CDK4 complexes [80,82,131,152,153]. Both proc-
esses are clearly dissociated in other situations, which
include the inhibition of the activity of D-type cyclin-
CDK4 complexes by cAMP or rapamycin in mouse macro-
phages [75], contact inhibition in 3Y1 rat fibroblasts
[154], senescence of human fibroblasts [155], antiestro-
gen treatment of MCF-7 breast cancer cells [156], calmod-
ulin inhibitors in human fibroblasts [157], and arrest of
cAMP-dependent mitogenic stimulation in dog thyrocytes
by forskolin deprivation [158,159], TGFβ [91] or inactiva-
tion of Rho proteins by Clostridium toxin B [160].
Inhibition by p21 or p27 is the most generally proposed
mechanism to explain the inactivity of D-type cyclin-
CDK4 complexes [59,63,161]. Thus, the activation of cyc-
lin D1-CDK4 complexes during G1 phase progression
depends on p27 disappearance [80,153], and is prevented
by up-regulation of p27 [75,154] or p21 [155,156]. This
obviously contrasts with the positive roles (stabilization
and nuclear anchoring) of these "inhibitors" on D-type
cyclin-CDK4 complexes, and the frequent observation
that they can support the pRb-kinase activity of CDK4
[162]. Whereas G1 arrest by cAMP in mouse macrophages
is associated with p27 up-regulation which inhibits cyclin
D1-CDK4 activity [75], in the cAMP-dependent G1-phase
progression of dog thyrocytes, an apparently similar eleva-
tion of p27 concentration allows the nuclear import and
activation of cyclin D3-CDK4 complexes, and both proc-
esses are prevented by TGFβ which inhibits the binding of
this complex to p27 [91]. Similarly, inhibition of cyclin
D1-CDK4 activity has been explained either by increased
[156] or decreased [104] binding of p21.
Labaer et al [90](in the case of p21 but not of p27) and
Blain et al [89](in the case of p27 but not of p21) have
interestingly shown that such opposite roles of CDK
"inhibitors" could depend on their stoichiometry relative
to a D-type cyclin in CDK4 complexes, as initially shown
for the dual action of p21 on cyclin A-CDK2 [163]. Never-
theless, structural studies indicate that cyclin A-CDK2
complexes can accommodate only one molecule of p21 or
p27, which fully inhibits the activity [164-166]. Moreo-
ver, according to Pledger and collaborators, only the
minor fraction of cyclin D3-CDK4 complexes devoid of
Cip/Kip proteins is active [93,95]. Our analysis of the
impact of graded concentrations of p27 relative to cyclin
D3 and CDK4 in CHO and Sf9 cells and in vitro, as well
as the comparison of their relative expression levels in
native systems where p27 supports or prevents CDK4
activity, fully confirm the "stoichiometric" model [82].
This implies two types of cyclin D3-CDK4-p27 complexes
depending on relative p27 concentrations: the first com-
prising a low stoichiometry binding of p27 and displaying
a pRb-kinase activity, and the second, inactive due to
additional p27 molecule(s). Whereas the association of
p27 to CDK complexes is generally believed to depend on
its binding to the cyclin [60,166], we have found both in
Sf9 and CHO cells, that p27 can avidly form binary com-
plexes with CDK4 in the absence of a D-type cyclin [82].
In native systems, we also observed a persistence of p27-
CDK4 complexes after the disappearance of labile D-type
cyclins provoked by protein synthesis inhibition [82,159].
This association of p27 with cyclin-free CDK4 in intact
cells is consistent with the model of different p27-binding
modes permitting the association of several p27 mole-
cules to D-type cyclin-CDK4 complexes.
The D-type cyclins/p27 ratio can thus contribute to deter-
mine the cell responsiveness to mitogens or growth inhib-
itory factors, which in turn act to modify this equilibrium
to levels that allow, or prevent, the concerted activation of
CDKs leading to S-phase entry [162]. In some circum-
stances, as in quiescent dog thyrocytes which express high
amounts of cyclin D3 [70] but low levels of p27 and p21,
p27 (in response to TSH) or p21 (in response to growth
factors [45]) rather than D-type cyclins may have to be up-
regulated to facilitate CDK4 activation. Similarly in mam-
mary gland and prostate of p27-null mice, epithelial cell
proliferation was reported to be impaired, whereas p27
haplo-insufficiency accelerated cyclin D1-dependent
transformation, which was prevented by normal p27
expression [167-169].
Some modulations of the activity of D-type cyclin-CDK4
complexes cannot be explained by modifications of their
association with p21 or p27 [82,157,158,160]. For
instance, in dog thyrocytes the withdrawal of the cAMP
stimulation rapidly arrests the entry of cells in S-phase and
pRb phosphorylation but does not reverse the formation
of nuclear cyclin D3-CDK4-p27 complexes [84,158].Page 7 of 16
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Phosphorylation is the least studied level of regulation of
CDK4. An inhibitory phosphorylation of CDK4 on Tyr17
was reported in UV irradiation-induced G1 arrest [170] or
during cell's arrest in quiescence [171] or in response to
TGFβ [172]. However, the group of Sherr failed to detect a
tyrosine-phosphorylation of CDK4 [77,173], in agree-
ment with the observation that CDK4, unlike CDK1 and
CDK2, is not an in vitro substrate of the Wee1 CDK tyro-
sine kinase [174]. On the other hand, by analysing human
D-type cyclin-CDK4 expressed in insect cells through bac-
uloviral infection, Kato et al. have demonstrated that the
activity of CDK4 requires its phosphorylation on Thr172
[77] within the activation loop. Thr172-phosphorylation
of CDK4 requires its binding to a D-type cyclin, while
T172A mutation of CDK4 does not affect its binding to
the cyclin [77]. Furthermore, this group showed that
mammalian cell extracts possess a CDK4-activating kinase
activity which was ascribed to CAK (cyclin H-CDK7) on
the basis of the immunodepletion of this in vitro activity
by a polyclonal CDK7 antibody [175]. Nevertheless, the
activity of nuclear CAK (CDK7) complexes has generally
been found to be constitutive and non-regulated during
cell cycle or mitogenic stimulations [82,175-177].
Thr172-phosphorylation of CDK4 is thus assumed to pas-
sively result from CDK4 binding to a cyclin and subse-
quent nuclear import. When it is inhibited within the
cyclin D1-CDK4 complex by cAMP or contact inhibition,
this was ascribed to increased binding of p27 [75,154],
which has been found to prevent the activating phospho-
rylation of CDKs by CAK in vitro [75,178-181].
Despite the fact that it is required for CDK4 activity
[77,82], the activating Thr172 phosphorylation of CDK4
has been infrequently investigated because of lack of
methodological tools. We have recently shown that the
high-resolution power of the two-dimensional (2D) gel
electrophoresis (isoelectric focusing and SDS-PAGE)
allows one to separate several phosphorylated and non-
phosphorylated forms of CDKs and to visualize their rel-
ative proportions in the different complexes [82,91,182].
At variance with CDK2 [182], only one major single phos-
phorylated form of CDK4 is observed in a variety of cell
types, including dog and human thyrocytes, human
fibroblasts, T98G glioma cells, Rat2 fibroblasts,...
([82,91,100], and our unpublished results). We have
identified this main phosphorylated form of CDK4 as
comprising the activating Thr172 phosphorylation, by the
analysis of the CDK4 T172A mutant, in vitro phosphor-
ylation by recombinant CAK, as well as the utilization of
first samples of a trial production (not yet commercial-
ized) of a Thr172 phosphospecific CDK4 antibody by Cell
Signalling Technology Inc. [82]. These tools were also use-
ful for the analysis of the corresponding (Thr177) phos-
phorylation of CDK6 [82]. In those cells, no
stoichiometrically (biologically) significant phosphor-
ylated form of CDK4 (except a very minor form that com-
prises the Thr172 phosphorylation and a possible second
undefined one) could contain the inhibitory Tyr17 phos-
phorylation. In human fibroblasts (even after UV irradia-
tion (Kooken, unpublished results)), the lack of Tyr17-
phosphorylated CDK4 contrasts with the major phospho-
rylation of CDK2 on Tyr15 [182], implying that activation
of CDK4 and CDK2 must very differently depend on
Cdc25 phosphatases.
As demonstrated by 2D-gel separation of CDK4, the
cAMP-dependent cell cycle regulation and its inhibition
by TGFβ in dog thyrocytes have provided the first exam-
ples of a regulation of the activating Thr172-phosphoryla-
tion of CDK4 independently of changes in its association
with cyclins and CDK « inhibitors » [82,91,159]. Upon
arrest of forskolin stimulation, which induces the rapid
inactivation of cyclin D3-CDK4-p27 complexes without
preventing their continued formation, Thr172-phosphor-
ylation of CDK4 disappears from the cyclin D3 com-
plexes. The association of CDK4 with cyclin D3 and its
activating phosphorylation within this complex are thus
separately controlled by cAMP [159]. The strong inhibi-
tion by TGFβ of the activity of cyclin D3-CDK4 complexes
in TSH (cAMP)-stimulated dog thyrocytes is also
explained by decreased Thr172-phosphorylation of
CDK4, even within the residual cyclin D3-CDK4 com-
plexes that remain associated with p27 [82,91]. The acti-
vating phosphorylation of CDK4 thus integrates the
opposite cell cycle controls by cAMP and TGFβ after for-
mation of cyclin D3-CDK4 complexes. Furthermore, in
T98G cells and Rat2 cells (unpublished data), serum stim-
ulation strongly activates constitutively formed cyclin D3-
CDK4 complexes at least in part by directly stimulating
the Thr172-phosphorylation of CDK4 [82]. This would
generalize the new concept that Thr172-phosphorylation
could be a latest regulated step that determines the cata-
lytic activity of CDK4, the phosphorylation of Rb family
proteins and thus the passage through the G1 phase
restriction point.
In all those examples, modifications of p27-binding to
CDK4 complexes were unlikely to explain the modula-
tions of CDK4 phosphorylation. Indeed, the proportion
of Thr172-phosphorylated CDK4 is similarly enriched in
D-type cyclin complexes and in CDK4 bound to p27 or
p21 [45,82,91,159], even at high relative expression levels
of p27 that preclude CDK4 activity [82]. At variance with
previous conclusions [75], p27 does not inhibit the activ-
ity of D-type cyclin-CDK4 complexes by preventing the
activating phosphorylation of CDK4.Page 8 of 16
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The mechanisms involved in the regulation of the phos-
phorylation of cyclin D3-bound CDK4 remain enigmatic.
In mammalian cells, the major CAK activity that phos-
phorylates CDK4/6, CDK2 and CDK1 is considered to be
constituted of cyclin H-CDK7-MAT1, which are also sub-
units of transcription factor II H [181,183,184]. In princi-
ple, (anti)mitogenic signalling cascades might regulate
the activity of CAK, its substrate specificity or its access to
CDK4. However, we got no evidence of a regulation of
CAK (CDK7 complex) expression or activity in dog thyro-
cytes and T98G cells [82], as most often reported [175-
177]. This might suggest that constitutive CAK (CDK7)
complexes could not be instrumental in the regulated
phosphorylation of CDK4. In addition to the observation
discussed above that Thr172-phosphorylation of CDK4 is
not prevented by inhibitory concentrations of p27, other
arguments call for a reconsideration of CDK4-activating
kinase(s). Whereas CDK7 activity is nuclear, deletion of
p27 NLS sequence relocalizes most of cyclin D3-CDK4-
p27 complexes in the cytoplasm without impairing phos-
phorylation of p27-bound CDK4 [82]. As analysed in the
same cyclin D3 co-immunoprecipitations in T98G glioma
cells, serum stimulates the activating phosphorylation of
CDK4 but not that of the related CDK6 [82]. Nevertheless,
the latter appears as a better substrate for recombinant
CAK (cyclin H-CDK7-Mat1) in the same experiments
[82], consistent with observations by others who suc-
ceeded to readily phosphorylate CDK2 and CDK6, but
not different CDK4 preparations, using recombinant CAK
[153,180].
Although CAK (CDK7) can unambiguously phosphor-
ylate and activate cyclin D3-bound CDK4 in vitro, other
regulated CDK4-activating kinase(s) might thus remain to
be discovered. They might even be different in distinct
mitogenic stimulations and selectively target CDK4 com-
plexed to cyclin D3 or cyclin D1. Some observations can-
not be easily explained by only one kinase activating the
different D-type cyclin-CDK4 complexes. Indeed, how
could TGFβ selectively inhibit the activating phosphoryla-
tion of CDK4 bound to cyclin D3 in dog thyrocytes stim-
ulated by TSH, without affecting the activity and
phosphorylation of CDK4 stimulated by EGF [91]? How
could EGF stimulate the phosphorylation and activity of
CDK4 bound to cyclin D1 in human thyrocytes, but not
the activity of abundant cyclin D3-CDK4 complexes,
which were specifically activated by TSH [100]?
Recent studies have also pointed out the Thr160 phospho-
rylation of CDK2 as a direct target of treatments that pre-
vent S-phase entry [185-188]. In some of these studies, the
activation of CDK4 [185,186] and/or the in vitro assayed
activity of CDK7 [185,188] remain unaffected, leading
their authors to suggest the involvement of distinct CAK
activities. In D. melanogaster, CDK7 is required for the acti-
vation of CDK1 complexes but not for phosphorylation
and activation of CDK2-cyclin E [189]. At variance with
nuclear cyclin H-CDK7 of animal cells, the cytoplasmic
monomeric Cak1p of budding yeast [190] preferentially
phosphorylates monomeric CDK2 and CDK6 in vitro,
and CDK inhibitors including p27 do not block this activ-
ity [180]. Several monomeric CAKs with distinct substrate
specificities coexist with CDK7 orthologs in plants
[191,192]. In human cells, a small distinct CAK activity
was enriched [193], and a candidate nuclear p42 CAK was
recently cloned [194]. Although the CDK2 phosphorylat-
ing activity of this p42 "CAK" has been disputed recently
[195], it seems that the debate about the nature of mam-
malian CAK(s) [181,183,184] is not coming closer to its
end.
Conclusion
The activation of CDK4 is a peculiarly complex process
requiring different successive steps, which are distin-
guished by their independent regulations. This allows to
better understand how CDK4 can function at the restric-
tion point as a master integrator of various mitogenic and
antimitogenic controls of the cell cycle. A few models,
including the physiologically relevant example of the thy-
roid primary culture system, have allowed to dissociate
the regulated assembly of D-type cyclin-CDK4 complexes
from the accumulation of their individual partners, the
nuclear import of these complexes from their assembly,
and the activating phosphorylation of CDK4 from the for-
mation and nuclear accumulation of the D-type cyclin-
CDK4-p27/p21 holoenzyme (Figure 1). We have identi-
fied this last step as an ultimate regulatory target deter-
mining CDK4 activity, pRb phosphorylation and the
passage through the G1 phase restriction point. Some evi-
dence is emerging that the activation process of the six
possible cyclin D1/2/3-CDK4/6 complexes could be sub-
ject to partly different regulatory mechanisms. Cyclin D3-
CDK6 complexes appears to be especially resistant to inhi-
bition by p16 [196] and p27 [197]. In T98G glioma cells,
serum stimulates the phosphorylation of cyclin D3-
bound CDK4 but not cyclin D3-bound CDK6 [82]. In thy-
rocytes, the distinct mitogenic pathways of growth factors
or TSH appear to be channeled to preferentially activate
and utilize CDK4 complexed to either cyclin D1 or cyclin
D3 [45,70,100] (Figure 1). This leads to partly different
phosphorylations of pRb, which might differentially
impact pRb function in the transcriptional regulation of
genes involved in cell cycle or differentiation [45,100].
The visualization of the phosphorylation profiles, as
resolved using 2D-gel electrophoresis, of CDK4 [82],
CDK2 [182] and CDK1 (Kooken and Coulonval, unpub-
lished results) has illustrated the different logics of their
regulations. Cyclin-CDK1/CDK2 accumulate as a reser-Page 9 of 16
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CDK4 regulation: the example of canine thyroid primary culturesFigure 1
CDK4 regulation: the example of canine thyroid primary cultures. Two distinct mitogenic modes coexist in dog thy-
rocytes and are differentially associated with differentiation expression. Growth factors (GF) activate CDK4 as in other sys-
tems, mainly by inducing cyclin D1 and also p21, which stabilizes the cyclin D1-CDK4 complex in the nucleus. The 
differentiation-associated cell cycle activation by TSH and cAMP is adjunctive to this basic control. It utilizes cyclin D3 synthe-
sized in response to insulin or IGF-I, and p27. cAMP activates CDK4 by promoting the assembly of the cyclin D3-CDK4 com-
plex, its association with nuclear p27, and finally the activating Thr172-phosphorylation of CDK4 within this complex by an 
undefined CDK4 activating kinase (CDK4AK). Activation of CDK4 complexed to cyclin D1 or cyclin D3 in these parallel 
mitogenic stimulations leads to partially different site-specificity of pRb-kinase activity. In this system, TGFβ selectively inhibits 
the cAMP-dependent activation of cyclin D3-CDK4, not by impairing the formation of this complex, but by preventing its bind-
ing to nuclear p27, as well as by inhibiting CDK4 phosphorylation within residual p27-bound cyclin D3-CDK4 complexes. The 
dog thyrocyte model illustrates the dissociation of the regulated assembly of D-type cyclin-CDK4 complexes from the accumu-
lation of their subunits, the dissociation of the nuclear import of these complexes from their assembly, and the dissociation of 
the rate-limiting phosphorylation of CDK4 from the formation and nuclear accumulation of the D-type cyclin-CDK4-p27/p21 


























































Cell Division 2006, 1:25 http://www.celldiv.com/content/1/1/25voir of inactive complexes containing both activating
(Thr161/160) and inhibitory (Tyr15 and Thr14) phos-
phorylations until their activation by dephosphorylation
of the inhibitory residues by Cdc25 phosphatases. On the
other hand, CDK4 activity could not be generally
restricted by substantial Tyr-phosphorylation, but by lack
of activating phosphorylation, at variance with the corre-
sponding phosphorylations of CDK2/1 by CAK which are
not thought to be rate-limiting.
CDK4 activity is crucial in various tumorigenesis models
and appears as a very attractive target for cancer therapy
[198]. As discussed in this overview, increased expression
of a D-type cyclin is clearly not sufficient to activate
CDK4, which likely explains the lack of relationship
between cyclin D1 overexpression and CDK4 activity in
neoplastic epithelial cell lines [199]. Mechanisms respon-
sible for the regulation of the assembly and activation of
D-type cyclin-CDK complexes are crucial but remain
largely enigmatic. They constitute obvious targets for
oncogenic mechanisms. Their elucidation thus remains a
major challenge that might lead to the discovery of new
therapeutic targets.
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